Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Meow, I'm not understanding your question about 13f.
invest, don't you find it curious that Jason Marks, EVP Chief Legal and Compliance Officer left abruptly after working at AMRN for 1 year. Something isn't right internal issues galore???
ILT, I sent a reply to the poster aek I didn't see that you posted the link. Spoofing happens almost daily with AMRN.
aek, thanks very interesting. I've watched AMRN for a few years and depending on the volume the spoofing occurs almost daily. Blocks show up a penny or two above the bid or ask then it disappears. Recently a block of 153,000 showed a few pennies above the ask then fades. It's a disgrace it definitely puts a lid on the price moving higher.
CBB, I believe Denner will file a universal proxy when Amarin files their 2023 proxy. So until then we will just have to wait it out. He has a plan but Denner is very much aware of who he's dealing with via KM's Egyptian mentality. I made sure of that....KM is full of himself and has no substance.
MMS, Since a settlement would be material, the company may issue a press release with a settlement announcement with some vague details but if it's sealed I believe they can't disclose exact details. They can file a statement with details with the SEC but it won't be a public document for the public to view. That's assuming they actually settle.
What's interesting is they have gradually been clearing their desk of lawsuits. Maybe a major BP won't partner with them till they get rid of all their legal baggage?
skipperdog, you are 100% correct. The shorts will take every share available to borrow and knock the price back down to $1. AMRN will not do a reverse split.
To Whom it may concern: Below is my email to IR, cc to KM and ADenner last night. Their reply showed up in my inbox at 4:45 today. You're welcome.
Lisa:
Did you or anyone notice that Vazkepa is misspelled in the body of the PR when they quoted Abuaf. Shame on you or whoever proofread this press release. Fire that person.
Where’s management???
Thank you for your email. We agree this should not happen. We took immediate steps yesterday for correction which was posted. We also added steps to the proofing and review process with the newswire.
Amarin IR
KNJS, six degrees of separation, James Healy COB of CINC
https://www.sofinnova.com/team/james-healy-md-phd/
Michael Kalb, CFO, CINC
https://www.marketwatch.com/story/cincor-pharma-taps-michael-kalb-as-cfo-271667827976
JT
https://cyteir.com/john-thero
Maybe Jason Marks will be next?
Meowzo, BRAVO. Knew you would catch it.
Kgeo, yes r is trademark symbol most people know that. But what my post was about is the misspelling of the one and only product amarin sells is VASCEPA/VAZKEPA.
You pointed that out in your post. Thank you.
Meowzo, you of all ppl should notice the misspelling of Vazkepa.
Read the content of the pr today. I'm not crazy just intent on pointing out the truth.
Jroon how do you spell Vazkepa? Please see my last post. Who ever quoted Abauf misspelled Vazkepa!
Please give me a break.
hey all you geniuses out there read the original post see below. There's NO r which indicates trademark. And If they can't insert a proper trademark they shouldn't be putting out PR's.
I think they corrected when it was bought to their attention.
Why are all of you people so freakin judgemental? Get a freakin life!
mivan
Re: ralphey post# 395145
Wednesday, December 07, 2022 3:02:29 PM
Post#
395169
of 395193
good news, I am just without words to see they misspelled the name...
https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-vazkepar-icosapent-ethyl-receives-regulatory
Laurent Abuaf, SVP and President Amarin Europe: “Today’s regulatory approval of VAZEKPA in Switzerland is an important step as we seek national pricing and reimbursement and consider building out our local Swiss operations in support of a commercial launch in 2023.
mivan, Thanks for the catch. I sent IR an email with a cc to KM and Denner asking who will correct the spelling of their one and only product. So inept beyond incredible.
Raf, add this to your wall of shame, please!!!
marjac, what's your take. Do you think maybe Amarin is clearing the calendar with all the BS lawsuits to move forward with a partnership so they have no overhang if a BP company feels they may be a good fit for their business structure????
mivan, LOL how stupid can they be? Especially since it's in the headline of the "Good News" feel good PEEE RRRRR...I fear it will only get worse. No revenues till 2025 don't hold your breath everyone!!!!!
capt, thanks so much for your help. Always appreciate it.
sleven, thanks I asked capt to convert to a google file and post. It appears that AMRN and DRL are going to mediation 2/23/23. If I'm correct this may end the legal issues for the time being until AMRN circles back to Hikma for infringement once they settle with HN. Hopefully!!!
meow, are you referring to the old times when people paid commish to buy or sell stock? Now the fees are hidden. When the comments come in from the broker/dealers it'll take the SEC a few years to make a move either way. Because there are always unintended consequences e.g. doing away with the uptick rule when the shorts go on the attack. I think you know what I mean after all I was in the business when times were "Wholesome" sounds like a Reddit emoji when someone plays the piano and sings pretty songs...
meow, what incentives do the market makers have to get in the middle of a trade so the order flow goes their way is the almighty dollar? Retail doesn't know what happens on the back of a napkin at Fraunces Tavern!
So in the legitimate world of market making it use to be the best bid and best offering but with most stocks trading in between the spread it makes it difficult to compete especially in the third market or dark pools. There's no transparency. And then there's spoofing! hehe
BBI, maybe it's the ESC congress going on in Milan where Dr. Giuseppe Biondi-Zoccai may discuss the potential for treating long covid with Vascepa????
The volume indicates something is brewing and it ain't coffee...
meow, please explain gating auction.
meowzo, it's about freakin time, Gensler isn't going to push this through he has no backbone, I'm being polite. I wonder how this will affect Robinhood's balance sheet?
SI has my attention.
https://escp.eu/search?term=master%27s+in+pharmaceutical+marketing+and+management
please scroll down to the section starting with Jallat and then check the date 2015. There was no degree offered in 1995 for marketing and management on the Berlin campus. In 2015 the degree KM claims to hold was offered in the Paris and London campuses.
It's not important anymore so everyone just drop it!
EducationEducation
ESCP Business School logo
ESCP Business SchoolESCP Business School
Master’s Degree, Biopharmaceutical Marketing and ManagementMaster’s Degree, Biopharmaceutical Marketing and Management
1994 - 19951994 - 1995
Cairo University logo
Cairo UniversityCairo University
Bachelor of Pharmacy - BPharm, Pharmacy & Pharmaceutical SciencesBachelor of Pharmacy - BPharm, Pharmacy & Pharmaceutical Sciences
1988 - 19931988 - 1993
Collège de la Sainte Famille logo
Collège de la Sainte FamilleCollège de la Sainte Famille
High School DiplomaHigh School Diploma
1976 - 1988
RMB, Thanks for posting, this could be an interesting session. I wonder where he's been for the past few years? Seriously, out of the blue he appeared???
https://esc365.escardio.org/person/1094
just to clarify a play on words. KM did not receive a marketing degree. He made it up as he went along after he had experience in marketing at Merck he added the wording to his degree when he created Theodon Consulting. Here's a reply from my source. Just for clarification and end of story!
The course introduced in Paris and London in 2015 is called:
- Advanced Master’s in Biopharmaceutical Management.
Now it is possible that KM’s concentration was in international marketing. But the precise degree does not mention “marketing”. The whole issue turns around the word Marketing and the omittance of Biotechnologies. Of course, Merck must have vetted him, but on his degree without “marketing”.
It is clear that KM wants, since leaving Merck in 2018, to point out in his CV his “expertise” in “marketing” and “commercialization” as he asserts in his Theonon Consultancy.
ILT we need a branded gv ASAP. our survival in the USA depends on that decision especially after many insurance companies are dropping coverage on V.
KM has walked away from the domestic market. We don't need to spend many precious
dollars defending the
trading of our stock we
need revenue. KM can
only cut expenses so
much then after that
the truth will be told
based upon lack of
growth. Then we're SOL. Denner is our only saving grace.
ILT, indeed spoofing has happened many times during any given day to AMRN except when the volume dries up. I try to watch the trading towards the close using one of Fidelities links for directed trades I see blocks show up and then fade the market on a daily basis. The orders aren't real then I see odd lots like 10 sh lots show up maybe 20 times just to give the appearance that there's action in the stock on the downside or upside then at the close a 1 share trade shows up .03 or .04 cents above the mkt or below. It's a penny stock with no respect!!!!
capt, you're very fortunate that your coverage is so great. I learned something today about the donut hole deal. What a farce. But in the meantime I had a conversation with a person from Caremark which is the PBM for Clover and other insurers. She explained some stuff about coverage I never understood and really didn't care till it happened to me...If anyone on IHub is on medicare see below. It's a generalized pdf of how these ins. companies are instructed to determine coverage. Of course, it's govt controlled so it is what it is. And it's state by state, it's a joke I think it's intended to be confusing so people who want to fight their coverage just give up due to frustration.
https://www.medicare.gov/Pubs/pdf/11136-Pharmacies-Formularies-Coverage-Rules.pdf
Invest the absolute worst thing that could happen to the stock is a reverse split. It's always a disaster and I mean always.
I don't believe Denner would let it go that far.
KM is full of himself. No wonder why his wife lives in nyack, ny and he lives in Switzerland.
North, I tried last night to open but it was in french and no available translation. I'll do further research to confirm. But my source has been spot on in the past. It doesn't seem to matter to most people I actually have begun to think KM is full of BS! Not just because of his BS cv but nothing he has said so far has turned into any sort of revenues from anywhere even in approved countries. Yet HLS is making progress albeit gradual. And with encouraging forecasts.
nuke, I have Clover Health they use Caremark CVS for my part D coverage. It depends on which state you reside in whether Clover is available.
north, please share the link. Thanks
north, I'm not saying he didn't graduate ESCP in 1995-96, the master's degree he claims to hold didn't start at the university till 2015.
shadolane, what it means is his character is that flawed to the extent he had to lie on his CV and begs the question can we trust the information he is telegraphing to the shareholders? So far his timeline for the anticipated approvals in the EU is very much in question.
I sincerely hope Denner now understands the kind of person KM really is and what his next move on the chess board is.
nuke, yup, and what's interesting is CVS ONLY covers Vascepa no generics.
Jasbg, it's real.
Shado, oh well someone screwed up. It's difficult to prove unless someone with extensive knowledge has access to information going back 25 yrs ago.
If you're inclined do your own search.
Let the truth be told. KM is not who he betrayed himself to be. Credit to anonymous.
THEODON was also present at the ESCP Business School Berlin campus in 1994 – 1995 when KM graduated with a Master’s Degree in Pharmaceutical Marketing and Management. Yet, no such degree was offered then.
Indeed, it was not until 2015 that Dr. Frédéric Jallat co-founded the Advanced Master in Biopharmaceutical Management (MsM – offered only at Paris and London campuses) of which he is PhD Professor and Academic Director. Please see:
https://escp.eu/news/training-healthcare-professionals-to-manage-data-driven-projects
and ESCP website
https://escp.eu/